PHAXIAM Therapeutics
Safia Arous is an experienced professional in the biotechnology sector, currently serving as a Business Development Associate at Phaxiam Therapeutics since February 2023, focusing on infectiology, phage-based therapy, health innovation, partnerships, intellectual property, and business intelligence. Prior to this role, Safia held the position of Business Development Project Leader at Erytech Pharma since January 2012, and served as a Project Leader at Alliospharma from December 2008 to December 2009. Additionally, Safia contributed to collaborative projects at Lyonbiopôle from January 2007 to November 2008.
This person is not in any teams
PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.